Shares of Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report) were up 11.1% during trading on Thursday. The company traded as high as C$0.20 and last traded at C$0.20. Approximately 296,140 shares were traded during mid-day trading, an increase of 241% from the average session volume of 86,934 shares. The stock had previously closed at C$0.18.
Medicenna Therapeutics Stock Performance
The company has a current ratio of 0.69, a quick ratio of 4.65 and a debt-to-equity ratio of -4.08. The company has a market cap of C$18.92 million, a P/E ratio of -0.93 and a beta of 2.49. The company has a 50 day moving average price of C$0.41 and a 200-day moving average price of C$0.52.
Medicenna Therapeutics (TSE:MDNA – Get Free Report) last issued its quarterly earnings data on Monday, November 16th. The company reported C($0.04) earnings per share (EPS) for the quarter. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 861.02%. On average, equities analysts expect that Medicenna Therapeutics Corp. will post -0.37 earnings per share for the current fiscal year.
Medicenna Therapeutics Company Profile
Medicenna is a clinical-stage immunotherapy company developing engineered cytokine therapies designed to selectively engage the immune system to treat cancer. The Company’s most advanced program, bizaxofusp (formerly MDNA55), is a targeted IL-4 Empowered Superkine that has been evaluated in more than 130 patients across five clinical trials, including a Phase 2b study in recurrent glioblastoma. Bizaxofusp has received Fast Track designation from the FDA and Orphan Drug designation in the United States and Europe.
See Also
- Five stocks we like better than Medicenna Therapeutics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
